Probabilistic modeling of cytomegalovirus infection under consensus clinical management guidelines

Transplantation

Volumn 87, Issue 4, 2009, Pages 570-577

  Dmitrienko, Svetlana ^a   Balshaw, Robert ^a   MacHnicki, Gerardo ^b   Shapiro, R Jean ^a   Keown, Paul A ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Antiviral treatment; Cytomegalovirus; Graft rejection; Kidney transplantation

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; GANCICLOVIR; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY;

ADULT; ARTICLE; COST BENEFIT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; BIOPSY; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; PATHOLOGY; POSTOPERATIVE COMPLICATION; PROBABILITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; T LYMPHOCYTE; VIROLOGY;

ADULT; ANTILYMPHOCYTE SERUM; ANTIVIRAL AGENTS; BIOPSY; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES AS TOPIC; PROBABILITY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; T-LYMPHOCYTES;

EID: 65649112415     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181949e09     Document Type: Article

References (44)

1. Lopez-Rocafort L, Brennan D. Current review of cytomegalovirus in renal transplantation. Minerva Urologica e Nefrologica 2001; 53: 145.
2. Toupance O, Bouedjoro-Camus M, Carquin J, et al. Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: A cohort study with case-control analyses. Transpl Int 2000; 13: 413.
3. Reischig T, Jindra P, Svecova M, et al. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. J Clin Virol 2006; 36: 146.
4. Sagedal S,Nordal K, HartmannA, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2: 850.
5. McCarthy J, Karim M, Krueger H, et al. The cost impact of cytomegalovirus disease in renal transplant recipients. Transplantation 1993; 55: 1277.
6. von Willebrand EP, Ahonen E, Hayry JP. CMV infection, class II antigen expression, and human kidney allograft rejection. Transplantation 1986; 42: 364.
7. Nett P, Heisey D, Fernandez L, et al. Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation. Transplantation 2004; 78: 1036.
8. Schnitzler MA. Costs and consequences of cytomegalovirus disease. Am J Health Syst Pharm 2003; 60: S5.
9. Reinke P, Fietze E, Ode-Hakim S, et al. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 1994; 344: 1737.
10. Borchers AT, Perez R, Kaysen G, et al. Role of cytomegalovirus infection in allograft rejection: A review of possible mechanisms. Transpl Immunol 1999; 7: 75.
11. McLaughlin K, Wu C, Fick G, et al. Cytomegalovirus seromismatching increases the risk of acute renal allograft rejection. Transplantation 2002; 74: 813.
12. Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184: 1461.
13. Dickenmann M, Cathomas G, Steiger J, et al. Cytomegalovirus infection and graft rejection in renal transplantation. Transplantation 2001; 71: 764.
14. Preiksaitis J, Brennan D, Fishman J, et al. Canadian Society of Transplantation Consensus Workshop on Cytomegalovirus Management in Solid Organ Transplantation Final Report. Am J Transplant 2005; 5: 218.
15. Dmitrienko S, Yu A, Balshaw R, et al. Biomarkers in transplantation: Model parameters from consensus guidelines for managementof CMV infection in renal transplantation. Kidney Int 2007 [Epub ahead of print].
16. Keown PA. New immunosuppressive strategies. Curr Opin Nephrol Hypertens 1998; 7: 659.
17. BuhaescuI, SegallL,GoldsmithD,et al. New immunosuppressive therapies in renal transplantation: Monoclonal antibodies. J Nephrol 2005; 18: 529.
18. Woodroffe R, Yao G, Meads C, et al. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: A systematic review and modelling study. Health Technol Assess 2005; 9: 1.
19. Keown PA, KiberdB,BalshawR,et al.Aneconomic model oftwo-hour post-dose cyclosporine monitoring in renal transplantation. Pharmacoeconomics 2004; 22: 621.
20. Keown PA, Balshaw R, Krueger H, et al. An economic model of Simulect in renal transplantation. Transplantation 2001; 71: 1573.
21. Akobeng A. Principles of evidence based medicine. Arch Dis Child 2005; 90: 837.
22. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
23. Kalbfleisch J, Prentice R. The statistical analysis of failure time data. 2nd ed. New York, John Wiley and Sons 2002.
24. Couchoud C, Cucherat M, Haugh M, et al. Cytomegalovirus prophylaxis with antiviral agents in solid organ-transplantation: A meta-analysis. Transplantation 1998; 65: 641.
25. Kletzmayr J, Kreuzwieser E, Watkins-Riedel T, et al. Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients. Transplantation 2000; 70: 1174.
26. Taber DJ, Ashcraft E, Baillie G, et al. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. Transpl Infect Dis 2004; 6: 101.
27. Lake K. New prophylactic treatment strategy for cytomegalovirus disease. Am J Health Syst Pharm 2003; 60: S13.
28. Uknis M. Prophylaxis of cytomegalovirus disease in transplant patients. Am J Health Syst Pharm 2005; 62: S3.
29. Brennan DC, Garlock KA, Lippmann BA, et al. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. J Am Soc Nephrol 1997; 8: 118.
30. Sagedal S, Nordal K, Hartmann A, et al. Pre-emptive therapy of CM-Vpp65 antigen positive renal transplant recipients with oral ganciclovir: A randomized, comparative study. Nephrol Dial Transplant 2003; 18: 1899.
31. Strippoli G, Hodson E, Jones C, et al. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006; 81: 139.
32. Schnitzler M, Lowell J, Hmiel S, et al. Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation: The importance of HLA-DR matching. J Am Soc Nephrol 2003; 14: 780.
33. Rubin R. Infection in the organ transplant recipient. In: Clinical approach to infection in the conpromised host. Plenum Medical Book Company, New York 1994, p 629.
34. Sagedal S, Nordal KP, Hartmann A, et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000; 70: 1166.
35. Brennan D, Garlock K, Singer G, et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 1997; 64: 1843.
36. Brennan DC. Cytomegalovirus in renal transplantation. J Am Soc Nephrol 2001; 12: 848.
37. Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 928.
38. Pouteil-Noble C, Ecochard R, Landrivon G, et al. Cytomegalovirus infection-an etiological factor for rejection? A prospective study in 242 renal transplant patients. Transplantation 1993; 55: 851.
39. Becker B, Becker Y, Leverson G, et al. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Am J Kidney Dis 2002; 39: 1088.
40. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66: 329.
41. Sagedal SH, Hartmann A, Rollag H. The impact of early cytomegalovirus infection and disease in renal transplant recipients. Clin Microbiol Infect 2005; 11: 518.
42. Hibberd P, Tolkoff-Rubin N, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995; 123: 18.
43. von Müller L, Schliep C, Storck M, et al. Severe graft rejection, increased immunosuppression, and active CMV infection in renal transplantation. J Med Virol 2006; 78: 394.
44. Isenberg AL, Shen GK, Singh TP, et al. Failure of ganciclovir prophylaxisto completely eradicate CMV diseasein renal transplant recipients treated with intense anti-rejection immunotherapy. Clin Transpl 2000; 14: 193.